Calcium and Vitamin D Supplementation in CKD with Osteoporosis

Introduction to CKD and Osteoporosis Management

The American Journal of Kidney Diseases recommends that in patients with CKD and osteoporosis, calcium and vitamin D supplementation should be prescribed with careful consideration of CKD stage, with a total elemental calcium intake of 800-1,000 mg/day and vitamin D supplementation to correct deficiency, while monitoring serum calcium, phosphate, and PTH levels 1, 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline, as published in the American Journal of Kidney Diseases, recommends a total elemental calcium intake of 800-1,000 mg/day (including dietary calcium, calcium supplementation, and calcium-based phosphate binders) for CKD stages 3-4 not taking active vitamin D analogs to maintain neutral calcium balance 1
For CKD stage 5D patients, the American Journal of Kidney Diseases suggests that calcium intake should be adjusted based on concurrent use of vitamin D analogs and calcimimetics to avoid hypercalcemia or calcium overload 1
The Kidney International journal recommends that calcium-based phosphate binders should be restricted in dose for CKD stages 3a-5D patients receiving phosphate-lowering treatment 3
The American Journal of Kidney Diseases recommends that the calcium-phosphorus product should be maintained below 55 to reduce the risk of extraskeletal calcification 4

The American Journal of Kidney Diseases recommends measuring 25-hydroxyvitamin D levels in CKD patients with elevated PTH, and supplementing if levels are <30 ng/mL 4, 5
For vitamin D deficiency in CKD stages 3-4, the American Journal of Kidney Diseases recommends ergocalciferol (vitamin D2) supplementation according to severity of deficiency 2
The Kidney International journal recommends that in CKD stages 1-5T (transplant), vitamin D deficiency and insufficiency should be corrected using treatment strategies recommended for the general population 6, 7

The American Journal of Kidney Diseases recommends monitoring serum calcium and phosphate levels at least every 3 months after initiating vitamin D therapy 4
The American Journal of Kidney Diseases suggests discontinuing ergocalciferol therapy if corrected total calcium exceeds 10.2 mg/dL or if serum phosphorus exceeds 4.6 mg/dL despite phosphate binder therapy 4
The Kidney International journal recommends that for CKD stages 3a-5, progressively rising or persistently elevated PTH levels should prompt evaluation for modifiable factors including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency 3, 8
The Kidney International journal recommends that the frequency of monitoring should increase in patients receiving treatments for CKD-MBD or with identified biochemical abnormalities 3, 7

The Kidney International journal recommends that in CKD stages 1-2 with osteoporosis and high fracture risk, management should follow general population guidelines 3
For CKD stages 3a-3b with normal PTH and osteoporosis/high fracture risk, the Kidney International journal recommends that treatment should also follow general population guidelines 3
The Kidney International journal suggests that in CKD stages 3a-5D with biochemical abnormalities of CKD-MBD, low BMD, and/or fragility fractures, treatment choices should consider the magnitude and reversibility of biochemical abnormalities and CKD progression 3, 7

The Kidney International journal recommends avoiding routine use of calcitriol or active vitamin D analogs in CKD stages 3a-5 not on dialysis; reserve for patients with severe and progressive hyperparathyroidism 3
The Praxis Medical Insights: Practical Summaries of Clinical Guidelines recommends that hypercalcemia must be avoided in adults with CKD stages 3a-5D 8
The Kidney International journal recommends that bone biopsy may be considered to guide treatment decisions in complex cases with CKD-MBD and osteoporosis 3, 7

The Kidney International journal and the American Journal of Kidney Diseases recommend assessing CKD stage and measuring serum calcium, phosphate, PTH, and 25(OH)D levels 3, 4
The American Journal of Kidney Diseases recommends correcting vitamin D deficiency if 25(OH)D <30 ng/mL using ergocalciferol supplementation 2, 4
The American Journal of Kidney Diseases recommends maintaining total elemental calcium intake at 800-1,000 mg/day in CKD stages 3-4 1
The Kidney International journal and the American Journal of Kidney Diseases recommend adjusting calcium and vitamin D supplementation based on regular monitoring of serum calcium, phosphate, and PTH levels 3, 4
The Kidney International journal recommends considering bone mineral density testing and fracture risk assessment to guide further treatment decisions 7
The Kidney International journal recommends that for advanced CKD (stages 4-5D) with osteoporosis, consider bone biopsy before initiating specific osteoporosis treatments 3